+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07145255

Phase 12 Study of MBRC-201 Antibody-Drug Conjugate to Find Safe Dose and Assess Treatment in Advanced Solid Tumors Unresponsive to Standard Therapies

Led by MBrace Therapeutics · Updated on 2026-02-17

150

Participants Needed

7

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating MBRC-201, an antibody-drug conjugate, in patients with advanced metastatic solid tumors that have not responded to standard treatments. This study includes multiple phases Phase 1a focuses on finding safe dose levels and the maximum tolerated dose, Phase 1b expands to evaluate safety and early clinical activity at chosen doses in specific tumor types including prostate, lung, breast, colorectal, and pancreatic cancers, and Phase 2 further assesses antitumor activity and safety at the recommended dose. The trial is open-label and conducted across multiple centers. The study involves giving MBRC-201 to patients in escalating doses during Phase 1a to identify optimal dosing. Phase 1b enrolls about 80 patients divided into four cohorts based on tumor type to understand safety and clinical effects. Following this, Phase 2 will include around 30 patients in tumor-specific groups to further evaluate the drug at the determined recommended dose. Throughout the phases, pharmacokinetics and immune response to MBRC-201 are monitored, and a Safety Review Committee oversees dosing and patient safety. Participants will undergo regular assessments including safety evaluations, tumor response measurements, and pharmacokinetic studies. The study tracks adverse events, dose-limiting toxicities, and long-term outcomes like progression-free survival and duration of response for up to 24 months. There is also a long-term follow-up period for safety, disease status, and survival that continues until death, loss to follow-up, or withdrawal. The total study duration is estimated to be about 48 months from first enrollment to completion of follow-up data.

CONDITIONS

Brief Title

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here